Develops therapies for autoimmune kidney diseases, led by atacicept for IgA nephropathy.
Develops therapies for autoimmune kidney diseases, led by atacicept for IgA nephropathy.
Has no approved product and earns no sales; spending on late-stage trials and launch preparation is funded by money raised from investors. Its lead drug, atacicept, was licensed from Merck KGaA, which would be owed milestone and royalty payments if it reaches the market.
Moat: none (IP / patents). Differentiated dual-pathway BAFF/APRIL mechanism but a competitive, fast-evolving IgA nephropathy field.
Headquarters: Brisbane, California, US · Founded: 2016 · Employees: 249
Size Vera Therapeutics (VERA) is a United States Health Care company (Biotechnology) with a market value of $1.85B, the 1820th largest of 3,085 United States companies the cockpit tracks. Shares closed at $25.58 on 18 Nov 2026.
Performance Over six months the shares fell 26.1%, against -4.7% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 19 in its peer set.
Growth The operating margin is -4,160.1% (peer median -8.7%).
Valuation It trades at 149.9× enterprise value to sales against a peer median of 10.9× (most expensive of 15).
Short interest Short interest is 16.8% of the free float (30 Oct 2026).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $10.3M | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $5.82M | -$468,000 | -$2.17M | $1.86M | $846,000 |
| EBITDA | -$426M | -$315M | -$165M | -$104M | -$91.7M |
| Net income | -$415M | -$300M | -$152M | -$96.0M | -$89.1M |
| Free cash flow | -$376M | -$242M | -$136M | -$92.2M | -$67.7M |
| Capital expenditure | $798,000 | $630,000 | $972,000 | $63,000 | $62,000 |
| Total debt | $75.4M | $77.3M | $54.6M | $53.7M | $31.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Vera Therapeutics VERA | $1.85B | -26% | n/a | -4,160% | 149.9× | n/a |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 6.2× | 1.6% |
| Travere Therapeutics TVTX | $4.82B | +16% | +49% | -3% | 7.6× | 17.3% |
| Caltagirone CALT.MI | $1.23B | +4% | +10% | 10% | 1.1× | 1.1% |
| Otsuka Hldgs 4578.T | $39.9B | +9% | +11% | 18% | 2.3× | 1.6% |
| Vertex Pharmaceuticals VRTX | $136B | +25% | +11% | 35% | 10.5× | 6.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VERA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.9% | -1.6% | 5th lowest of 20 |
| 6-month return | -26.1% | -4.7% | 4th lowest of 19 |
| Distance from 52-week high | -54.4% | -33.4% | 3rd lowest of 21 |
| Operating margin | -4,160.1% | -8.7% | lowest of 15 |
| EV / Sales | 149.9× | 10.9× | most expensive of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Vera Therapeutics VERA | United States | $1.85B | -26% | n/a | -4,160% | 149.9× | n/a | n/a |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $1.86B | -20% | -9% | 6% | 4.9× | 22.7% | +3.4% |
| Hemab Therapeutics COAG | United States | $1.83B | +48% | n/a | n/a | n/a | n/a | n/a |
| First Tracks Biotherapeutics TRAX | United States | $1.87B | +175% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $1.88B | +41% | +337% | -76% | 14.7× | n/a | n/a |
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 2.4× | -11.0% | +117.9% |
| Lycia Therapeutics LYCA | United States | $1.81B | n/a | -55% | -593% | n/a | n/a | n/a |
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | 13.6× | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | 146.1× | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | 10.2× | n/a | n/a |
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 11.7× | 33.0% | +24.8% |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | 18.8× | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | 50.6× | n/a | n/a |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 3.6× | -12.1% | +15.0% |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 5.0× | 3.5% | +41.4% |
| Evopoint Biosciences 688837.SS | China | $2.08B | n/a | n/a | n/a | 53.6× | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.64B | -31% | +71% | 0% | 4.2× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 1.7× | -7.6% | +33.5% |